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OBJECTIVEdToexamine thepatterns and associationsof insulin regimens andchange in regimens
with clinical outcomes in a diverse population of children with recently diagnosed type 1 diabetes.
RESEARCHDESIGNANDMETHODSdThe study sample consisted of youth with type
1 diabetes who completed a baseline SEARCH for Diabetes in Youth study visit after being newly
diagnosed and at least one follow-up visit. Demographic, diabetes self-management, physical,
and laboratory measures were collected at study visits. Insulin regimens and change in regimen
compared with the initial visit were categorized as more intensive (MI), no change (NC), or less
intensive (LI). We examined relationships between insulin regimens, change in regimen, and
outcomes including A1C and fasting C-peptide.
RESULTSdOf the 1,606 participants with a mean follow-up of 36 months, 51.7% changed to
an MI regimen, 44.7% had NC, and 3.6% changed to an LI regimen. Participants who were
younger, non-Hispanic white, and from families of higher income and parental education and
who had private health insurance were more likely to be inMI or NC groups. Those inMI andNC
groups had lower baseline A1C (P = 0.028) and smaller increase in A1C over time than LI (P,
0.01). Younger age, continuous subcutaneous insulin pump therapy, and change to MI were
associated with higher probability of achieving target A1C levels.
CONCLUSIONSdInsulin regimens were intensified over time in over half of participants but
varied by sociodemographic domains. As more intensive regimens were associated with better
outcomes, early intensification of management may improve outcomes in all children with di-
abetes. Although intensification of insulin regimen is preferred, choice of insulin regimen must
be individualized based on the child and family’s ability to comply with the prescribed plan.
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The Diabetes Control and Complica-tion Trial (DCCT) clearly establishedthe benefits of intensive versus con-
ventional insulin therapy in adolescents
and adults with type 1 diabetes (1). Im-
proved glycemic control, measured by
lower A1C levels, reduced the risk for on-
set and progression of long-term diabetes
microvascular and macrovascular com-
plications (2).
Since the DCCT was conducted, sig-
nificant advances in diabetes manage-
ment have occurred, including newer
and more physiologic insulin analogs,
sophisticated blood glucose monitoring,
and insulin delivery technologies such as
continuous subcutaneous insulin pump
therapy (CSII) and continuous glucose
monitoring (CGM). Current recommen-
dations from the American Diabetes
Association (ADA) and International So-
ciety for Pediatric and Adolescent Di-
abetes endorse the use of intensive
insulin regimens in most pediatric pa-
tients. Additionally, the ADA recom-
mends the following age-specific A1C
goals for children: ,6 years of age, 7.5–
8.5%; 6–12 years, #8.0%; 13–18 years,
#7.5%; and .19 years, #7.0% (3).
However, it is unclear whether intensive
insulin regimens used in clinical pediat-
ric diabetes care result in different A1C
outcomes (4,5).
The SEARCH for Diabetes in Youth
study has reported that insulin treatment
regimens were cross-sectionally associ-
ated with sociodemographic, clinical,
and metabolic characteristics among
youth with type 1 diabetes (6). Sociode-
mographic factors were strongly associ-
ated with insulin regimen used, with
participants more likely to be using inten-
sive regimens, such as CSII, if they were of
non-Hispanic white race/ethnicity and
from families with higher income and
higher parental education, and had pri-
vate health insurance. CSII therapy was
associated with lowest A1C levels in all
age-groups. Higher frequency of blood
glucose monitoring was also associated
with a lower A1C within each treatment
group. No significant differences were ob-
served in the frequency of hypoglycemia
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or emergency department visits between
insulin regimen groups; however, fre-
quency of hospitalizations was lower in
participants who were on CSII therapy
than other insulin regimens. Overall, ado-
lescents had unacceptably high A1C lev-
els, with 70% having levels .7.5%
regardless of insulin regimen.While these
observations yield valuable information
about insulin regimens and A1C out-
comes, gaps in our existing knowledge re-
sult in limited evidence-based guidelines
to indicate how such regimens can be ap-
plied most optimally over time to individ-
uals with varied resources.
There is a paucity of information
about changes in insulin regimens and
outcomes over time, particularly early in
the clinical course of type 1 diabetes. In
the DCCT, intensive therapy was associ-
ated with preserved b-cell function,
which in turn was associated with im-
proved glycemic control and decreased
risk of severe hypoglycemia. In fact, cur-
rent immuno-intervention trials are de-
signed to preserve b-cell function and
attempt to account for the effect of inten-
sive therapy by ensuring that the control
group as well as treatment group(s) are
closely followed andmanaged with inten-
sive regimens (7,8). However, there is lit-
tle information regarding the role of
insulin treatment regimens in preserva-
tion of b-cell function and short-term
outcomes.
This report describes a cohort of
participants from the SEARCH study
who have been followed over time with
an initial visit in the first year after di-
agnosis, providing an opportunity to
examine whether insulin regimen inten-
sification over time significantly impacts




Overview of the SEARCH study
SEARCH is an ongoing multicenter study
that conducts population-based ascer-
tainment of newly diagnosed cases of
nongestational diabetes in youth ,20
years of age (9). For this study, youth
with diabetes were identified in geograph-
ically defined populations inOhio,Wash-
ington, South Carolina, and Colorado;
among managed health care plan enroll-
ees in Hawaii and California; and among
Indian Health Service beneficiaries in se-
lected American Indian populations. Ca-
ses are considered valid if diagnosed by a
health care provider. For all validated
cases, core demographic and diagnostic
information, including date of birth,
sex, date of diagnosis, and clinical dia-
betes type, was obtained from medical
records, usually as part of the case vali-
dation process. The clinical diabetes
type assigned by the health care profes-
sional was obtained from medical
records or physician reports and catego-
rized as follows: type 1 (combining type
1, type 1a, and type 1b), type 2, and
other types (including hybrid type, ma-
turity onset diabetes of the young, type
unknown by the reporting source, type
designated as other, and missing type).
Self-reported race and ethnicity infor-
mation was collected through an initial
survey using the 2000 U.S. Census
questions (10).
Youth with nonsecondary diabetes
who replied to the initial survey were
invited to a baseline study visit while
metabolically stable (no episode of di-
abetic ketoacidosis during the previous
month). On average, visits occurred 10
months after diabetes diagnosis. Partici-
pants who were diagnosed in 2002–2005
were also invited back for follow-up study
visits at ~12 and 24months after the base-
line visit. Written informed consent and
assent were obtained according to guide-
lines established by the local institutional
review boards.
Study population
For this report, participants were in-
cluded if they had type 1 diabetes, were
taking insulin, and had a baseline and at
least one follow-up study visit. Partici-
pants were excluded if key measures,
including insulin treatment regimen,
A1C, and fasting C-peptide (FCP), were
missing. The final study sample included
1,606 youth with type 1 diabetes who
had a baseline and at least 1 follow-up
visit; 76% of those had at least two follow-
up visits.
Data collection
After an 8-h, overnight fast, participants
attended a study visit. Participants were
instructed not to take diabetes medica-
tions the morning of the visit except for
basal insulin administered by a continu-
ous insulin infusion pump. Physical ex-
aminations at the study visits were
conducted according to standardized
protocols by trained and certified staff
members. Height and weight were mea-
sured to the nearest 0.5 cm and 0.1 kg.
BMI was calculated as weight in kilograms
divided by the square of height in meters
and converted to BMI z score using the
standard Centers for Disease Control
and Prevention approach (11). At the vis-
its, information was collected on demo-
graphics, duration of diabetes, household
income, highest level of education of ei-
ther parent/guardian, health insurance
status, and type of provider delivering di-
abetes care (e.g., pediatric endocrinolo-
gist, adult endocrinologist, family
practitioner). Blood was drawn to mea-
sure A1C and FCP.
A1C was measured by a dedicated
ion-exchange high-performance liquid
chromatography instrument (Tosoh Bio-
science, San Francisco, CA). FCP was
measured by a two-site immunoenzymet-
ric assay (Tosoh Bioscience). The assay
sensitivity is 0.05 ng/mL.
Self-reported information obtained
at the time of the study visit used for
these analyses included history of in-
sulin use, number of daily injections,
types of insulin, mode of insulin delivery
(e.g., insulin syringes or insulin pen
devices, CSII), and frequency of self–
blood glucose monitoring (SBGM). Ad-
ditional information was collected by
self-report related to acute clinical com-
plications occurring within the 6months
prior to the study visit, including epi-
sodes of severe hypoglycemia (defined
as “very low blood sugar that required
you to get help”), hospital admission,
or emergency department visits. The
same data were also collected at follow-
up visits.
Treatment regimens
Insulin regimens were classified into five
categories, with category 1 considered
most intensive and category 5 least in-
tensive, as follows: 1) basal-bolus with
CSII; 2) basal-bolus with glargine or de-
temir plus rapid-acting insulin (insulin
lispro, insulin aspart, or insulin gluli-
sine); 3) multiple daily injections
(MDIs) (three or more injections) with
glargine or detemir insulin plus NPH in-
sulin plus regular or rapid-acting insu-
lin; 4) MDI (three or more injections)
with any insulin types excluding basal
insulin (glargine or detemir); and 5)
one to two injections per day, excluding
insulin glargine or detemir. These cate-
gories represented basal-bolus regimens
(regimens 1 and 2), modified basal-bolus
regimens (regimen 3), MDIs (regimen 4),
or what had been considered standard
therapy at the initiation of the DCCT
(regimen 5).
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Change groups
Participants’ insulin regimens were catego-
rized based on the insulin regimen used at
baseline compared with their regimen at
their most recent follow-up visit. Those
who changed to a more intensive (MI) reg-
imen included those moving from a higher
to lower category, e.g., from regimen 4,
MDIs without basal insulin, to regimen 1,
CSII. The no change (NC) group is the
group who stayed in the same category.
The less intensive (LI) moved from a lower
to higher category, e.g., moving from regi-
men 2, basal-bolus, to regimen 5, one to
two injections/day without basal insulin.
Table 1dDemographics of participants by insulin regimen change group
MI NC LI P**
n 830 718 58
Age at baseline visit, years, mean (SD) 9.4 (4.0) 10.3 (4.6) 12.1 (4.3) ,0.0001
Age at diagnosis, years, mean (SD) 8.2 (4.0) 9.0 (4.6) 10.6 (4.2) ,0.0001
Duration of diabetes at baseline, months, mean (SD) 8.7 (5.8) 10.6 (6.3) 13.2 (7.2) ,0.0001
Duration of diabetes at follow-up 1, months, mean (SD) 22.5 (6.9) 24.3 (6.9) 27.1 (8.8) ,0.0001
Duration of diabetes at follow-up 2, months, mean (SD) 34.8 (6.8) 36.2 (7.4) 38.9 (7.7) ,0.0001
Sex
Male 418 (49.7) 392 (/46.6) 31 (3.7) 0.2471
Female 412 (53.9) 326 (42.6) 27 (3.5)
Race
Black 49 (35.5) 82 (59.4) 7 (5.1) 0.0003
Hispanic 83 (47.7) 84 (48.3) 7 (4.0)
Other 44 (43.6) 50 (49.5) 7 (6.9)
White 654 (54.8) 502 (42.1) 37 (3.1)
Household income (USD)
,25,000 82 (37.3) 126 (57.3) 12 (5.5) ,0.0001
25,000–49,000 162 (47.0) 167 (48.4) 16 (4.6)
50,000–74,000 165 (50.9) 146 (45.1) 13 (4.0)
$75,000 364 (59.7) 236 (38.7) 10 (1.6)
DK/refused 57 (54.3) 41 (39.1) 7 (6.7)
Maximum parental education
Less than high school graduate 23 (34.3) 37 (55.2) 7 (10.5) ,0.0001
High school graduate 98 (42.2) 122 (52.6) 12 (5.2)
Some college through associates degree 268 (48.4) 266 (48.0) 20 (3.6)
Bachelor’s degree or more 441 (58.6) 292 (38.8) 19 (2.5)
Health insurance
Private 694 (54.6) 531 (41.8) 47 (3.7) ,0.0001
Medicaid/Medicare 111 (39.0) 163 (57.2) 11 (3.9)
Other 16 (76.2) 5 (23.8) 0 (0.0)
None 7 (30.4) 16 (69.6) 0 (0.0)
Type of diabetes care provider
Pediatric endocrinologist 671 (52.2) 574 (44.6) 41 (3.2) 0.0153
Adult endocrinologist 2 (14.3) 10 (71.4) 2 (14.3)
Generalist 14 (37.8) 20 (54.1) 3 (8.1)
Nurse practitioner/physician’s assistant 133 (54.3) 102 (41.6) 10 (4.1)
Other 9 (39.1) 12 (52.2) 2 (8.7)
Insulin regimen at baseline*
1 0 (0.0) 108 (83.7) 21 (16.3) ,0.0001
2 197 (38.0) 299 (57.7) 22 (4.3)
3 53 (44.5) 58 (48.7) 8 (6.7)
4 155 (66.2) 72 (30.8) 7 (3.0)
5 425 (70.1) 181 (29.9) 0 (0.0)
Center
A 166 (52.0) 140 (43.9) 13 (4.1) 0.0005
B 147 (51.9) 125 (44.2) 11 (3.9)
C 267 (56.7) 194 (41.2) 10 (2.1)
D 60 (40.3) 79 (53.0) 10 (6.7)
E 174 (52.9) 146 (44.4) 9 (2.7)
F 16 (29.1) 34 (61.8) 5 (9.1)
Data are n (%) unless otherwise indicated. N = 1,606. **P values are from ANOVA for continuous variables and x2 tests of association for categorical variables.
*1, pump; 2, MDI: glargine/rapid; 3, MDI: glargine/rapid plus other; 4, MDI: no glargine; and 5, one to two injections/no glargine. DK, don’t know.
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Statistical analyses
Statistical analyses were conducted using
SAS (version 9.2; SAS Institute, Cary,
NC). Outcome variables with skewed
distribution were log transformed. De-
mographic measures were summarized
by their mean (SD) or n (%) for categorical
measures. Comparisons of means and cat-
egorical frequencies across the three insu-
lin regimen change groups were tested
using ANOVA or the x2 statistic. The
number of participants, mean (SE) A1C
at baseline, and mean A1C at last follow-
up exam are presented by the insulin reg-
imen group at baseline comparedwith the
insulin regimen group at last follow-up.
The means (SE) of the outcome measures
are presented by change group and visit.
The adjusted means (least square means)
(SE) were estimated using repeated-
measures ANCOVA. The covariates includ-
ed the measure of the outcome at baseline
and age, race/ethnicity, research site,
household income, health insurance sta-
tus, and parental education. Contrasts
were formed to make pairwise compari-
sons between the change groups at each
of the follow-up visits. The adjusted
means (SE) of the outcomes were esti-
mated for each most recent insulin regi-
men and visit adjusting for the covariates
listed above. The equality of the adjusted
means across the five insulin regimens was
tested using ANCOVA musing contrasts
to test the equality separately at each of
the visits. Themeans (SD) of A1C are given
by change group by visit by whether the
subject was testing blood glucose four or
more times a day. For each change group
by visit, the means of A1C by whether they
test four or more times per day were com-
pared and tested using a two-sample t test.
The adjusted means (SE) were estimated
using ANCOVA, adjusting for the demo-
graphic factors listed above as covariates,
and the groups were compared for each
change group by visit. The percent of par-
ticipants that achieved the ADA target A1C
at last follow-up was compared by the x2
test separately for three age-groups.
RESULTSdDemographic and clinical
characteristics of the participants, by in-
sulin regimen change group, are shown in
Table 1. Between baseline and most re-
cent follow-up visit, just over half of the
participants (51.7%) changed to an MI
regimen, 44.7% had no change, and
3.6% changed to an LI regimen. Most
(76%) of the participants had two fol-
low-up visits; only 2% of these partici-
pants had an interval change at the first
follow-up that was not consistent with the
direction of change at the most recent
follow-up. Age, diabetes duration, socio-
demographics, and type of provider for
diabetes care differed significantly be-
tween change groups (Table 1). The MI
group was younger than NC and LI (P ,
0.0001), with shorter duration of diabetes
at each visit (P, 0.0001); was more likely
to beNHW (P = 0.0003); and had a higher
household income (P , 0.0001) and a
higher parental education level (P ,
0.0001). Those in the MI group were
more likely to have private health insur-
ance and to be seen by a pediatric endo-
crinologist than those in the LI group
(P, 0.0001 and P = 0.015, respectively).
There was a significant intensification of
insulin therapy over the duration of the
study in this large diverse population. At
baseline, the MI group had a lower pro-
portion of participants on more intensive
management and a higher proportion on the
least intensive regimen than either the NC or
the LI groups. Of the participants who were
on regimen 4 or 5 at the initial visit, 63.3%
were on more intense regimens at the most
recent follow-up visit, with 25.6% on CSII
therapy at follow-up. Of note, in the NC
group 108 (15%) were on CSII (insulin
regimen category 1) at their baseline visit and
407 (56%) were in either insulin regimen
category 1 or 2 at baseline, indicating an
already intensive regimen at baseline.
Figure 1dA: Visit, mean A1C during follow-up by regimen change group, unadjusted. C, MI;
-, NC; ▲, LI. B: Visit, A1C during follow-up adjusted for baseline values of A1C, FCP, and
demographics by regimen change group. Demographics include race, sex, research site, age,
duration of diabetes, maximum parental education, family income, and health insurance.C, MI;
-, NC; ▲, LI; bb, MI , LI, P , 0.01; cc, NC , LI, P , 0.01.
30 DIABETES CARE, VOLUME 36, JANUARY 2013 care.diabetesjournals.org
Longitudinal insulin regimen in type 1 diabetes
Treatment change group, A1C, and
achieving ADA A1C targets
At baseline, the LI group had a higher
A1C than the MI and NC groups (P =
0.028) (Fig. 1A). While A1C increased
significantly over time in all groups, after
adjustment for repeated measures, base-
line A1C, and demographics, theMI had a
lower A1C over time than the NC at both
the 1-year and 2-year visits (P , 0.05)
(Supplementary Table 1). Both MI and
NC showed a smaller increase in A1C
compared with the LI group (Fig. 1B).
Children ,6 years old were more likely
to achieve the ADA target level for A1C
representing good glycemic control, and
those.12 years old were least likely to do
so regardless of change group (Fig. 2). Of
note, the majority of children .6 years of
age did not achieve the ADA target for A1C
regardless of change group. CSII therapy
shows a significantly lower A1C at each
follow-up time point (P, 0.001), adjusted
for demographics, even though CSII users
had lowest FCP over time (P , 0.001)
(Supplementary Table 2). Overall younger
age, CSII therapy, and change to MI were
associated with higher probability of meet-
ing optimal target AIC levels before and
after adjustment for demographics.
A1C and self-glucose monitoring
The majority (86–91%) of participants re-
ported testing blood glucose at least four
times daily. At all visits and in all treatment
regimens, those testing at least four times/
day had lower mean A1C levels (Supple-
mentary Table 3). After adjustment for
baseline age, duration of diabetes, sex,
household income, parental education,
and type of health insurance, this trend con-
tinued. In almost all comparisons at the two
follow-up times, the mean level of A1C was
significantly lower in the case of testing four
or more times per day unadjusted or ad-
justed for demographic factors.
FCP
Mean FCPwas 0.69 ng/mL at baseline with
no significant differences among NC, MI,
and LI groups (Fig. 3A). In all groups, FCP
declined (P, 0.0001) over time. After ad-
justment for baseline FCP and demograph-
ics, FCP was significantly higher in LI and
NC versus MI (P , 0.01) (Fig. 3B).
BMI z score was not significantly dif-
ferent between change groups at any time
point (Supplementary Table 2). Similarly,
BMI was not different by insulin regimen
and did not increase over time more dra-
matically on any particular regimen (Sup-
plementary Table 3).
Hypoglycemic events were not differ-
ent by change group at any time point
(Supplementary Table 2). Participants in
the MI group had fewer emergency de-
partment visits than those in LI at the
follow-up visit 2 (P , 0.05), but there
was no difference in frequency of hospi-
talizations by change group.
CONCLUSIONSdTo our knowledge,
this is the first report of change in insulin
regimen over time in a contemporary
cohort of youth with type 1 diabetes.
At enrollment or over the course of
this study, a majority of participants
either used or moved to an intensified
insulin therapy regimen. By a mean
diabetes duration of ~36 months, almost
three-quarters of participants were using
basal-bolus therapy as either CSII or
MDIs. Sociodemographic factors were
highly associated with treatment regi-
men and the likelihood of moving to an
MI regimen. Specifically, higher parental
education, higher family income, and
having private health insurance were all
positively associated with an intensifica-
tion of insulin regimen over time. These
data are consistent with cross-sectional
studies reporting an association of socio-
demographics with treatment regimen.
Participants on intensified insulin
regimens had lower A1C levels over
time. This difference remained significant
when adjusted for baseline A1C. After
adjusting for sociodemographic variables
(age and race/ethnicity), the difference in
A1C between groups was less striking.
However, the LI group still had persis-
tently higher A1C than MI or NC groups.
Our results are similar to those observed
in retrospective study from a single
academic pediatric practice, where inten-
sive insulin regimens started at diagnosis
were associated with improved glycemic
control in patients on private insurance
and were not associated with worse gly-
cemic control in those on the public
health plan, Medicaid (12).
Important differences between these
studies are that the results we present are
from a longitudinal study of participants
from six different research sites, each
including a mix of academic versus non-
academic practices. Also, a focus of our
study was to assess whether change in
regimen was associated with improved
outcomes, as was the case. Furthermore,
SEARCH participants using CSII at their
final visit had lower A1C than those using
other treatment regimens regardless of
baseline treatment regimen.
An integral part of intensive self-
management of diabetes is frequent glu-
cose monitoring. The frequency of four or
more blood glucose tests/day (87.3%) at
baseline indicates that frequent glucose
monitoring is endorsed by diverse prac-
tice models across the U.S. and also
documents the intensity of care recom-
mended at diagnosis. Furthermore, the
82% overall report of this frequency of
glucose monitoring at the follow-up visit
confirms families’ understanding that
continuing glucose monitoring is an im-
portant component of diabetes care. Im-
portantly, over time, glucose monitoring
at a rate of four or more tests/day was as-
sociated with lower A1Cwithin all change
regimens, which validates the essential
nature of frequent glucose testing to
guide more optimal diabetes care. This
Figure 2dAge-group, percent meeting ADA target A1C at follow-up by regimen change group,
and age-group, unadjusted. Open bar, LI; gray bar, NC; dark bar, MI.
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association of more frequent glucose mon-
itoring for children on various insulin regi-
mens with lower A1C has been observed in
cross-sectional studies, including SEARCH
(6,13,14). Additionally, the proportion of
participants with less frequent monitoring
varied by change group, at baseline and
follow-up, as shown in Supplementary Ta-
ble 4; at visit 2, 45%of those in the LI group
were monitoring between zero and three
times/day compared with 23.8% in the
NC group and 13.5% in the MI group.
This observation also strongly suggests
that adherence to self-management tasks
was poorer in the LI group and likely influ-
enced the choice of insulin treatment regi-
men.
A decline in FCP levels occurred in all
insulin regimen groups. Intensified in-
sulin therapy did not appear to provide
protection against the temporal decline in
FCP. In fact, those in the LI group had a
higher FCP than the MI and NC groups
with and without adjustments. This may
be due to the fact that providers may
recommend less intensive insulin regi-
mens to youth with more preserved b-cell
function. Also, the LI group was older,
which may explain both their higher
mean FCP at baseline and the more grad-
ual rate of decline. Given the descriptive
nature of the study, it is not possible to
determine factors contributing to treat-
ment recommendations. However, inten-
sification of insulin therapy over time was
associated with better glycemic control,
which was not attributable to preserved C-
peptide. Because FCP was lower in more
intense regimens, we speculate that these
participants may have experienced greater
glucose variability, more significant hyper-
glycemia, and/or higher A1C at clinical vis-
its, prompting their care providers to
intensify the treatment regimen. On the
other hand, it is worth pointing out that al-
though the LI group had higher FCP levels,
this did not result in better glycemic control,
and some of these individuals may benefit
from insulin treatment intensification.
These data support an approach to
diabetes management that includes an
intensification of insulin regimen over
time. The fact that the more intensive
and no change groups were not signifi-
cantly different in a fully adjusted model
reflects, in part, the high frequency of
starting on rather intensive therapies, e.g.,
basal-bolus in the NC group. The fact that
A1C was most strongly associated with
insulin regimen at follow-up also speaks to
the importance of intensification over time.
The data also emphasize the importance of
identifying better therapies for all youth
with diabetes. Also, as consistently reported
in cross-sectional studies, there is a need
for additional work in identifying the bar-
riers to care in adolescents, given that only a
minority is achieving acceptable glycemic
control. These data do provide U.S. bench-
marks from a large, diverse population for
A1C values over time as well as frequency of
hypoglycemia, emergency department vis-
its, and hospitalizations in children with
type 1 diabetes cared for outside of a ran-
domized, controlled trial.
Limitations to this report include the
fact that these findings may not be gener-
alizable to all children with diabetes.
While there was much effort to recruit
and encourage visits for all eligible par-
ticipants, participation in research studies
is elective. Older youth are less likely to
participate (15). In our study population,
those in the LI groupwere older and had a
longer duration of diabetes. While longer
duration is associated with a higher A1C
and lower FCP, duration was included in
our regression model to account for this
important variable; therefore, the findings
in the LI group are likely to reflect the larger
SEARCH population. At this time, we are
unable to comment on factors contributing
todecisions related todiabetesmanagement
in the SEARCH cohort, including insulin
regimen and frequency of glucose monitor-
ing. Subsequent follow-up of SEARCH par-
ticipants is designed to address some of
these factors, including additionalmeasures
of barriers tomore optimal glycemia such as
Figure 3dA: Visit, mean FCP during follow-up visits by regimen change group (unadjusted).C,
MI;-, NC; ▲, LI. B: Visit, mean FCP during follow-up by regimen change group adjusted for
baseline FCP and demographics. (Demographics include race, sex, clinic, age, duration of di-
abetes, maximum parental education, income, and insurance.)C, MI;-, NC;▲, LI; aa, MI,
NC, P , 0.01; aaa, MI , NC, P , 0.001; b, MI , LI, P , 0.05.
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fear of hypoglycemia and out-of-pocket ex-
penses for diabetes supplies.
The strengths of this study include its
large, racially/ethnically and socioeconom-
ically diverse composition. This is an ob-
servational study frommultiple centers and
encompasses participants whose care is
delivered in a variety of practice models
ranging from academic multidisciplinary
specialty clinics to public health centers.
Also, the longitudinal nature of the study
allowed for building on SEARCH’s previ-
ous cross-sectional reports, including the
key finding that intensification of insulin
regimens over time was associated with
better glycemic control.
In conclusion, for the majority of
youth in this study, insulin regimen in-
tensified over time, and more intensive
regimens were associated with lower
A1C. However, health care inequities
were observed in that minority youth
and those from families with lower in-
come and less parental education were
less likely to have their insulin regimens
intensified. Frequent glucose monitoring
was highly associated with better glycemic
control within all treatment regimens, re-
flecting that this is an essential component
to optimal diabetes care. More intensive
management was not associated with a
slower decline in C-peptide levels. Because
intensive diabetes care is generally associ-
ated with higher supply costs, it may be
subject to scrutiny by payer systems. Tak-
ing together the better outcomes but socio-
demographic disparities in intensification
of insulin regimens, there is a dire need to
develop strategies to improve care for all
children with diabetes.
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